This year's American Academy of Neurology annual meeting takes place April 15-21, 2016 in Vancouver, British Columbia.
Cognitive and Psychiatric Impairment in Parkinson
Can we see changes in the brain that correspond to cognitive difficulties? Research presented at AAN 2016 offers compelling information.
Exploratory Trial for Essential Tremor Treatment
In a proof-of-concept study, 25 patients were exposed to a dose-escalating infusion of SAGE-547 to evaluate the drug’s effect on essential tremor.
Modeling Simulations to Predict AED Efficacy
Researchers used simulations to predict the outcomes of epilepsy patients with partial-onset seizures converting to Aptiom monotherapy (800 mg QD).
Potential Treatment for SRSE
Research leading up to the ongoing phase 3 trial of SAGE-547, a potential drug for super-refractory status epilepticus, was presented at AAN 2016.
Antiepileptic Drug Choice: Patient vs Neurologist
Do you and your patients with epilepsy agree on treatment decisions? A national survey compares AED attribute preferences of patients and neurologists.
Clinical Trial Highlights: AAN 2016 – Part 1
From no evidence of disease activity in MS to studies of a new treatment for periodic paralysis, AAN 2016 featured many exciting clinical trials.
Zika Possibly Tied to Another Autoimmune Disorder
In addition to Guillain-Barré syndrome, a small study from Brazil discussed Zika virus and a possible tie to another autoimmune disorder at AAN 2016.
Botulinum Toxin: Guideline Updates
Two authors of the updated AAN guidelines for treatment with botulinum neurotoxin discussed their findings and potential avenues of further research.
By clicking Accept, you agree to become a member of the UBM Medica Community.